Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Biotheus: Clinical Trials & FDA Approval Profile

Biotheus (Global / Institutional) sponsors 15 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 10 active protocols (2 recruiting now), 2 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)0.0%
Median Closed Enrollment vs National (145 pts)39 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Biotheus
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)15
Active Pipeline (Recruiting Now)10 (2)
Completed vs Stopped Early2 / 0 (0.0%)
Median Closed Actual Enrollment39 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Biotheus
Hospital Research SiteLocationShared Protocols
Harbin Medical University Cancer HospitalHarbin, Heilongjiang8
Jilin Cancer HospitalChangchun5
Zhejiang Cancer HospitalHangzhou, Zhejiang5

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Biotheus
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07133750PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal CancerPhase IIRECRUITING
NCT06419621PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBCPhase IIIACTIVE NOT RECRUITING
NCT05844150A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLCPhase IIACTIVE NOT RECRUITING
NCT05864105PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular CarcinomaPhase IICOMPLETED
NCT05918107A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPMPhase IICOMPLETED

Explore interactive annual charts and M&A subsidiary rollups in the Biotheus Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI